NCT02201992 2025-12-19
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting